Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months
Malaria Journal, Volume 8, No. 1, Article 163, Year 2009
Notification
URL copied to clipboard!
Description
Background: Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune and semi-immune adults. A phase Ib dose-escalating study was conducted to assess the vaccine's safety and immunogenicity in children aged 12 to 24 months in Korogwe, Tanzania (ClinicalTrials.gov number: NCT00469651). Methods: This was a double-blind, randomized, controlled, dose escalation phase Ib trial, in which children were given one of two different doses of the MSP3 antigen (15 g or 30 g) or a control vaccine (Engerix B). Children were randomly allocated either to the MSP3 candidate malaria vaccine or the control vaccine administered at a schedule of 0, 1, and 2 months. Immunization with lower and higher doses was staggered for safety reasons starting with the lower dose. The primary endpoint was safety and reactogenicity within 28 days post-vaccination. Blood samples were obtained at different time points to measure immunological responses. Results are presented up to 84 days post-vaccination. Results: A total of 45 children were enrolled, 15 in each of the two MSP3 dose groups and 15 in the Engerix B group. There were no important differences in reactogenicity between the two MSP3 groups and Engerix B. Grade 3 adverse events were infrequent; only five were detected throughout the study, all of which were transient and resolved without sequelae. No serious adverse event reported was considered to be related to MSP3 vaccine. Both MSP3 dose regimens elicited strong cytophilic IgG responses (subclasses IgG1 and IgG3), the isotypes involved in the monocyte-dependant mechanism of Plasmodium falciparum parasite-killing. The titers reached are similar to those from African adults having reached a state of premunition. Furthermore, vaccination induced seroconversion in all vaccinees. Conclusion: The MSP3 malaria vaccine candidate was safe, well tolerated and immunogenic in children aged 12-24 months living in a malaria endemic community. Given the vaccine's safety and its induction of cytophilic IgG responses, its efficacy against P. falciparum infection and disease needs to be evaluated in Phase 2 studies. © 2009 Lusingu et al.
Authors & Co-Authors
Lusingu, John Peter Andrea
Unknown Affiliation
Gesase, Samwel
Unknown Affiliation
Msham, Salum
Unknown Affiliation
Francis, Filbert
Unknown Affiliation
Lemnge, Martha M.M.
Unknown Affiliation
Seth, Misago Dimson
Unknown Affiliation
Sembuche, Samwel H.
Unknown Affiliation
Rutta, Acleus S.M.
Unknown Affiliation
Minja, Daniel Thomas Remias
Unknown Affiliation
Segeja, Method D.
Unknown Affiliation
Bosomprah, Samuel
Unknown Affiliation
Cousens, Simon Nicholas
Unknown Affiliation
Noor, Ramadhani Abdallah
Unknown Affiliation
Chilengi, Roma
Unknown Affiliation
Druilhe, Pierre L.
Unknown Affiliation
Statistics
Citations: 39
Authors: 15
Affiliations: 5
Identifiers
Doi:
10.1186/1475-2875-8-163
e-ISSN:
14752875
Research Areas
Disability
Infectious Diseases
Maternal And Child Health
Study Locations
Tanzania